the core of our corporate values
Hangzhou, China, 15 November 2021- Zylox-Tonbridge (2190.HK, the "Company") announced the Company has signed a collaboration agreement with Sky Road. Under the agreement, Sky Road has grante...
On September 27th, Zylox-Tonbridge (2190.HK), one of the leading players in neuro- and peripheral- interventional medical device market in China, announced that the neurovascular embolization coils in...
On September 23, Zylox-Tonbridge announced that the Shareholders’ Meeting has approved the H-share incentive trust scheme proposed by its Board of Directors. The trust scheme is intended to give equi...
On August 23, Zylox-Tonbridge (2190.HK) announced that Tonbridge GyclineTM Microcatheter, a product independently developed by Zhuhai Ton-bridge Medical Technology Co., Ltd. (hereinafter referred to a...
Zylox-Tonbridge (2190.HK) recently announced that it has respectively set up an office in Beijing and a R&D center in Shanghai to attract more outstanding industry talents and promote the rapid an...
On July 12, 2021, ZYLOX-TONBRIDGE (2190.HK) announced that the Company has successfully completed enrollment in the PEVENSEY study. The PEVENSEY study is a prospective multicenter randomized controlle...